Alnylam Pharmaceuticals (ALNY) Share-based Compensation (2009 - 2026)

Alnylam Pharmaceuticals (ALNY) has 18 years of Share-based Compensation data on file, last reported at $86.6 million in Q2 2026.

• Quarterly Share-based Compensation fell 22.43% year-over-year to $86.6 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $336.6 million (up 10.06% YoY) and the FY2025 annual result came in at $348.2 million, up 27.99% from the prior year.
• Share-based Compensation rose to $86.6 million in Q2 2026, from $70.2 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $128.1 million in Q3 2022 to a low of $29.3 million in Q1 2022.
• A 5-year average of $68.3 million and a median of $67.0 million in 2023 frame the typical range for Share-based Compensation.
• Annual changes were most pronounced in 2022 — Share-based Compensation jumped 283.97% — and 2023, when it slumped 50.1%.
• Tracing ALNY's Share-based Compensation over 5 years: stood at $42.8 million in 2022, then retreated by 1.81% to $42.0 million in 2023, then soared by 118.23% to $91.6 million in 2024, then retreated by 21.84% to $71.6 million in 2025, then climbed by 20.93% to $86.6 million in 2026.
• The last three Share-based Compensation figures came in at $86.6 million (Q2 2026), $70.2 million (Q1 2026), and $71.6 million (Q4 2025), per Business Quant data.